![]() ![]() Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Available online: (accessed on 6 December 2022). COPD Guidelines: A Review of the 2018 GOLD Report. The authors declare no conflict of interest. Although the impact of muscle mass is controversial, skeletal muscle is an endocrine organ with multiple metabolic functions such as energy homeostasis, heat regulation, insulin sensitivity, and amino acid metabolism. In our study, no association was observed between mortality and ASMMI or low muscle mass defined according to EWGSOP2 (in men, ASMMI < 7.0 kg/m 2 and in women, ASMMI < 6.0 kg/m 2). In contrast, other studies have observed no association with exacerbations, days of hospitalization, quality of life, and mortality. Regarding the impact of low muscle mass on prognosis, the evidence is not conclusive some studies show that low muscle mass is a predictor of overall mortality in some populations, such as COPD patients and geriatric people. In COPD patients with low FFMI, lower muscle strength has been observed compared with normal FFMI. Skeletal muscle is the human body’s largest organ and accounts for 40–50% of total body weight under physiological conditions. p < 0.05 was considered statistically significant. Due to collinearity, body composition and BODE index variables were not included in the model. Subsequently, the multivariate Cox proportional hazards model was adjusted by clinical variables p < 0.100 in the bivariate model. Finally, bivariate Cox’s proportional hazards analysis was performed to evaluate the impact of body composition and sarcopenia on mortality. A comparison among study groups was analyzed with a chi-square test or Fisher’s F test for categorical variables and unpaired Student’s t-test or Mann–Whitney U tests for continuous variables. The Shapiro–Wilk test was used to test the normality of continuous variables continuous variables with normal distribution were presented as mean and standard deviation, and non-normal variables were presented as median and percentiles 25–75. Categorical variables were presented as frequencies and percentages. Conclusion: Low PhA, low muscle strength, and sarcopenia are independently associated with poor prognosis in COPD patients.Īnalyses were performed using a commercially available STATA version 14 (Stata Corp., College Station, TX, USA). Results: 240 patients were evaluated, of whom 32% had sarcopenia. Low strength and muscle mass, and sarcopenia were defined according to EWGSOP2. Body composition was assessed by bioelectrical impedance analysis. Patients with cancer, and asthma were excluded. Methods: A prospective cohort study performance was conducted with COPD patients. Our aims were to evaluate whether low strength, low muscle mass, and sarcopenia impacted mortality in COPD patients. However, according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), the impact of these alterations on mortality in COPD patients is not well-established. Body composition alterations are associated with adverse outcomes. Background: Patients with chronic obstructive pulmonary disease (COPD) have alterations in body composition, such as low cell integrity, body cell mass, and disturbances in water distribution evidenced by higher impedance ratio (IR), low phase angle (PhA), as well as low strength, low muscle mass, and sarcopenia. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |